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BACKGROUND
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Introduction: The 340B Drug Discount Program required drug manufacturers
provide discounted outpatient drugs to healthcare organizations which serve
vulnerable patient populations to allow these institutions to offer more services
to more people. As the 340B program expanded, controversy has centered on
which entities have benefited from the program. Many healthcare organizations
sold 340B drugs to well-insured patients at full price, and thus have been
financially rewarded.
Amendments to the program have permitted 340B
providers to utilize contract pharmacies to dispense 340B medication, which has
furthered the debate over which stakeholders are benefiting from the program.

As many as one-third of Americans living at or below 200% of the federal
poverty level have struggled to afford even modest prescription drug
expenses (Bright et al., 2010). The United States (U.S.) government created
the Medicaid Rebate Program in 1990 to provide lower-income Americans
with assistance with prescription drug expenses (340B Health, 2016).
However, this law had the unintended consequence of incentivizing drug
manufacturers to discontinue charitable discounts to safety-net providers to
ensure that average prices were kept high for purposes of establishing
Medicaid rebate rates (von Oehsen, Doggett, & Davis, 2012). Thus, in 1992
Congress created the 340B Drug Discount Program (hereinafter 340B) as part
of the Veterans Health Care Act of 1992 (Baer, 2015).

Purpose of the Study: The purpose of this study was to determine which
stakeholders benefited because of the 340B Drug Discount Program, and what
have been the drivers of recent changes to the program.
Methodology: This study utilized a literature review. One database aggregator
and 6 academic databases were used to collect 70 total sources. These sources
were reviewed and reduced to 39 sources which were used in the written
research. Of these, 20 sources were used in the Results section.
Results: Research showed that 340B eligible entities and contract pharmacies
have financially benefited from the 340B program. Patient benefit has been
indirect, as qualified providers have expanded service offerings and increased
access to healthcare services. Regulatory reform, as well as profit potential,
have driven the expansion of 340B as more providers have expanded eligible
service lines.
Discussion/Conclusion: The 340B program has realized its purpose in allowing
healthcare organizations serving vulnerable populations to expand access
opportunities to these patient populations through increased capacity and
expanded services. While the goal of the 340B program has often been
misconstrued, direct financial benefits to eligible providers have allowed for this
expansion of access.
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RESULTS
RESULTS
How 340B Discounts Work
•

----------

The purpose of this study was to determine which stakeholders benefited
because of the 340B Drug Discount Program, and what have been the
drivers of recent changes to the program.

This study hypothesized that the 340B Drug Discount Program provides direct
positive financial benefit to eligible providers and an indirect benefit to
vulnerable patient populations.
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The methodology for this study consisted of a qualitative literature review.
Research articles and peer-reviewed literature were located using Marshall
University’s EbscoHost, CINAHL, ProQuest, and PubMed research
databases.
A professional presentation was also utilized as a source of research for
vital data that contributed to the literature review. The information gained
from these articles, websites, and presentation were used as the sources
of primary and secondary materials.

Impact of 340B on Contract Pharmacies
• Contract pharmacies are no longer required to have a specific
geographical relationship with a health organization (Eagle et al., 2013).
• The move has significantly contributed to the growth of the program by
increasing the number of different pharmacies serving as contract
pharmacies by over 200% between 2010 and 2017 (HRSA, 2017).
• In 2014, Walgreens made up 38% of all contract pharmacy
arrangements in the 340B program as over 70% of the chain’s locations
participated in at least one contract pharmacy arrangement (340B
Reform, 2014).
Impact of 340B on Patients
• Both insured and uninsured patients at an eligible 340B entity can be
treated with deeply discounted drugs under the 340B program. These
discounts have ranged from 30% - 50% off the drug’s list price though
these cuts were not necessarily directly passed on to the patient (Conti
& Bach, 2014).
• The program has also improved access to medications used to treat
chronic conditions such as diabetes and asthma among the indigent
(340B Informed, 2016).
• The management of such chronic conditions cost an average of $3,000
per patient annually that has created a financial burden on patients
(Centers for Disease Control and Prevention, 2015). This reference
matches the references section.
Health Reform and Medicaid Expansion
• The primary driver of overall growth in the 340B program has been
health reform due to the implementation of the PPACA which expanded
Medicaid eligibility.
Organic Growth of the 340B Program
• Through the expansion of services, hospitals have driven organic
growth in 340B through increased volumes that would qualify for 340B
savings (Traynor, 2014).
• Duke University reported having generated profits of $282 million for
drugs under the 340B program by increasing its locations over a 5-year
period (Conti & Bach, 2014).
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METHODS
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340B mandated that drug manufacturers provide discounted outpatient
drugs to certain healthcare organizations which provided services to
vulnerable patient populations (42 U.S.C.S. 256b, 2015). These “covered
entities” had to either receive money from federal grants or be included in
one of six categories of hospitals, the most common of which was called a
Disproportionate Share Hospital (DSH), meaning that it served a
disproportionate share of the vulnerable patient population (340B Health,
2016). The stated purpose of the program has been to allow healthcare
providers to stretch federal resources so that these providers could offer
more services to more patients (Mulcahy, Armstrong, Lewis, & Mattke, 2014).

OBJECTIVE
OBJECTIVE

HYPOTHESIS
HYPOTHESIS

•

Impact of 340B on Providers
• Considering outpatient prescription medicine caters towards a
significant number of conditions that affect the low-income populations
Due to the variability in the type of outpatient drugs and their importance
regarding curing common illnesses among low-income people, the
amount of discount on eligible drugs has remained between 20% and
30% (Mascardo, Spading & Abramowtiz, 2012).
• Hospitals and large healthcare organizations such as Fenway
Community Health Center, Inc. in Massachusetts, and Cedars-Sinai
Medical Center in California, have reported discounts between 30% and
50% (Community Oncology Alliance, 2014).

This study concerned a timely topic that is a vital importance to many hospitals
and other 340B covered entities. Many healthcare organizations rely on
340B profits to subsidize their budget, allowing them to expand and
increase services to vulnerable populations. It is critically important that
the ongoing debate over the 340B program consider the original purpose
of the program and the myriad of ways vulnerable populations are
benefiting from the program.
As 340B has continued to expand, political advocacy has been successful in
creating controversy over the direct financial benefit that healthcare
providers and contract pharmacies have realized because of the program.
However, vulnerable and underserved patient populations have also
benefited in the form of expanded services and increased access to
healthcare. This type of benefit, while indirect, has fulfilled the intent of the
340B program at its inception.
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